The placental 11beta-hydroxysteroid dehydrogenase type 2 (11beta-
INTRODUCTION
Proper glucocorticoid (GC) exposure in utero is essential for normal fetal development, because insufficient [1, 2] and excessive [3] GC exposure lead to impaired organ maturation and fetal growth restriction (FGR), respectively. One key regulator of GC exposure during fetal life is placental 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2; encoded by the HSD11B2 gene), which serves as a functional barrier to protect the fetus from exposure to high levels of maternal GC by converting maternal cortisol to its inactive metabolite, cortisone [4, 5] . Indeed, 11b-HSD2 deficiency due to point mutations in the HSD11B2 gene is associated with FGR in the human [6] , and HSD11B2 À/À mice exhibit FGR phenotype [7] . Importantly, placental 11b-HSD2 activity and expression are reduced in human pregnancies complicated with FGR [8] [9] [10] [11] [12] [13] . Collectively, these findings highlight a crucial role for placental 11b-HSD2 in fetal development, and possibly in the pathogenesis of FGR. Consequently, a thorough understanding of its regulation is required and represents a key component of our overall understanding of the molecular mechanisms that govern normal and abnormal fetal development.
Over the past 20 yr following the discovery and subsequent cloning of 11b-HSD2, tremendous progress has been made regarding the regulation of 11b-HSD2 in the human placenta. It is known that placental 11b-HSD2 is under dynamic regulation by a wide range of intrinsic and extrinsic factors, the actions of which are mediated by several signal transduction pathways at both transcriptional and posttranscriptional levels [14] . However, our understanding of placental 11b-HSD2 regulation is incomplete. For example, the factors responsible for reduced placental 11b-HSD2 in pregnancies complicated by FGR remain largely unknown. Although we previously identified cadmium as a potent inhibitor of placental 11b-HSD2 in vitro [15] , which suggested that reduced placental 11b-HSD2 may contribute to the molecular mechanisms underlying cadmiuminduced FGR, the signal transduction pathway that mediates the effects of cadmium has not been defined. Furthermore, we also demonstrated recently that the p38 MAPK (MAPK14) is a key positive regulator of placental 11b-HSD2 [16] , but it remains unknown if the other two MAPKs, namely ERK1/2 (MAPK1) and JNK (MAPK8), also modulate placental 11b-HSD2. Therefore, the present study was designed to address these two outstanding questions using our established primary human trophoblast cells as an in vitro model system.
MATERIALS AND METHODS

Reagents and Supplies
The [1, 2, 6, H(N)]-cortisol (80 Ci/mmol) was purchased from DuPont Canada Inc. Nonradioactive cortisol and cortisone were obtained from Steraloids Inc. CdCl 2 , U0126, and SP600125 were purchased from SigmaAldrich Canada Ltd. Polyester-backed thin-layer chromatography (TLC) plates were obtained from Fisher Scientific Ltd. All solvents used were from VWR Canlab. Cell culture supplies were obtained from either Invitrogen Life Technologies or Fisher Scientific. General molecular biology reagents were from Invitrogen or Pharmacia Canada Inc.
Primary Trophoblast Cell Cultures
Placental trophoblast cells were isolated using a modification of the method of Kliman et al. [17] , as described [18] . Ethics approval for the entire study was obtained from the University of Western Ontario Ethics Board for Health Sciences Research Involving Human Subjects, and informed written consent was obtained from all participants involved in this study. Briefly, human placentas were obtained from uncomplicated pregnancies at term after elective cesarean section. Villous tissues were dissected free from fetal membranes and blood vessels, rinsed in 0.9% w/v NaCl, and digested with 0.125% v/v trypsin and 0.02% w/v deoxyribonuclease-I (Sigma) in Dulbecco modified Eagle medium containing 0.05% w/v streptomycin and gentamicin (Invitrogen) for 60-80 min. The placental cells were loaded onto a 5%-70% v/v Percoll (Sigma) gradient at step increments of 5% Percoll and centrifuged at 2500 3 g for 20 min to separate different cell types. Cytotrophoblasts between the density markers of 1.049 and 1.062 g/ml were collected and plated in 24-well plates at a density of 1.35 3 10 6 cells/ml in M199 containing 10% fetal calf serum (FCS; Invitrogen). The cells were maintained at 378C in humidified 5% CO 2 -95% air (20% O 2 ) for 48 h. We have shown previously that the isolated cytotrophoblasts will differentiate into syncytiotrophoblasts over 48 h of culture under conditions of the present study [18] . After the end of 48 h, the trophoblast cells (in triplicate) were treated for 24 h (or as indicated otherwise) with various compounds (as indicated in figure legends) in the medium containing 2% FCS. Controls, also in triplicate, received equivalent volume of vehicle (ethanol or dimethyl sulfoxide).
Assay of 11b-HSD2 Activity-Radiometric Conversion Assay
The level of 11b-HSD2 activity in intact cells following different treatment regimes was determined by measuring the rate of cortisol to cortisone conversion, as described previously [18] . Briefly, human trophoblast cells were incubated for 1 h at 378C in serum-free medium containing approximately 100 000 dpm [ 3 H]-cortisol and 100 nM unlabeled cortisol. At the end of incubation, the medium was collected and steroids extracted. The extracts were dried and the residues resuspended. A fraction of the resuspension was spotted on a TLC plate that was developed in chloroform/methanol (9:1, v/v). The bands containing the labeled cortisol and cortisone were identified by UV light of the cold carriers, cut out into scintillation vials, and counted in Scintisafe Econo 1 (Fisher Scientific). The rate of cortisol to cortisone conversion was calculated, and the blank values (defined as the amount of conversion in the absence of cells) were subtracted and expressed as percentage of control. Results are shown as mean 6 SEM.
Protein Extraction and Western Blot Analysis
Western blot analysis was used to determine various protein levels, as described previously [14, 19] . Briefly, human trophoblast cells were lysed in SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% w/v SDS, 10% v/v glycerol, 50 mM dithiothreitol, and 0.01% w/v bromophenol blue). Equal concentrations of the whole cell lysates were subjected to a standard 12% SDS-PAGE. After electrophoresis, proteins were transferred to PVDF transfer membrane (Hybond-P; Cat# RPN303F; Amersham) using a Bio-Rad Mini Transfer Apparatus. Nonspecific antibody binding was blocked with 5% w/v milk in TTBS (0.1% v/v Tween-20 in TBS) for 1 h at room temperature. Membranes were then hybridized with primary antibody (human 11b-HSD2, a generous gift from Dr. Z. Krozowski [20] , 0.25 lg/ml; human phospho-p38 MAP kinase [Thr180/Tyr182], Cat# 9211, Cell Signaling; human p38 MAP kinase, Cat# 9212, Cell Signaling; human phospho-p44/42 MAP kinase [Thr202/Tyr204], Cat# 9101, Cell Signaling; human p44/42 MAP kinase, Cat# 9102, Cell Signaling; phospho-SAPK/JNK, Cat# 9251S, Cell Signaling; human SAPK/JNK, Cat# 9252, Cell Signaling; the Phospho-Akt Pathway Sampler Kit, Cat #9916, Cell Signaling; human glyceraldehyde phosphate dehydrogenase, Cat# IMG-5567, Imgenex Corporation) overnight at 48C. All primary antibodies were used at 1:1000 dilutions. Membranes were always probed with anti-phospho-protein antibody first. They were then stripped by incubation in stripping buffer (100 mM 2-mercaptoethanol, 2% SDS, and 62.5 mM TrisHCl pH 6.7) for 30 min at 558C, blocked, and reprobed with the corresponding anti-total-protein antibody. After 3 3 10 min washes with TTBS, the membrane was incubated with the appropriate horseradish peroxidase-labeled secondary antibody, either anti-rabbit (Cat# HAF008; 1:500; R&D Systems) or antimouse (Cat# G-202-C; 1:10 000; R&D Systems) for 1 h at room temperature. Following another 3 3 10 min washes in TTBS, proteins were detected by chemiluminescence (Western Lightning Plus-ECL; Cat# NEL103001; PerkinElmer Life and Analytical Sciences). The membrane was then exposed to xray film (Eastman Kodak) for 1-60 min.
Assessment of 11b-HSD2 mRNA-Real-Time Quantitative RT-PCR
The relative abundance of 11b-HSD2 mRNA was assessed by a two-step real-time quantitative RT-PCR (qRT-PCR), as described previously [21] .
Briefly, total RNA was extracted from cultured cells using RNeasy Mini Kit (Qiagen Inc.) coupled with on-column DNase digestion with the RNase-Free DNase Set (Qiagen) according to the manufacturer's instructions. One microgram of total RNA was reverse transcribed in a total volume of 20 ll using the High Capacity cDNA Archive Kit (Applied Biosystems) following the manufacturer's instructions. For every RT reaction set, one RNA sample was set up without reverse-transcriptase enzyme to provide a negative control. Gene transcript levels of 28S rRNA (housekeeping gene) and 11b-HSD2 were quantified separately by custom-designed SYBR Green I chemistry-based assays [21] . Briefly, primers (300 nM each) for human 11b-HSD2 (sense: 5 0 -GGC CAA GGT TTC CCA GTG A-3 0 ; antisense: 5 0 -CAG GGT GTT TGG GCT CAT GA-3 0 ) and those (100 nM) for 28S rRNA (sense: 5 0 -TTG AAA ATC CGG GGG AGA G-3 0 ; antisense: 5 0 -ACA TTG TTC CAA CAT GCC AG-3 0 ) were designed with the Primer Express Software (Applied Biosystems), and the optimal concentrations were determined empirically. The SYBR Green I assays were performed with the SYBR Green PCR Master Mix (Applied Biosystems) and a modified universal thermal cycling condition (2 min at 508C and 10 min at 958C, followed by 40 cycles of 10 sec each at 95, 60, and 728C) with the standard disassociation/melting parameters (15 sec each at 95, 60, and 958C) on the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). The specificity of the SYBR Green I assays was verified by performing melting curve analyses and by subsequent sequencing of the PCR products.
Levels of 11b-HSD2 mRNA and 28S rRNA in each RNA sample were quantified by the relative standard curve method (Applied Biosystems). Briefly, standard curves for 11b-HSD2 and 28S rRNA were generated by performing a dilution series of the untreated control cDNA. For each RNA sample, the relative amount of 11b-HSD2 mRNA and 28S rRNA was obtained, and the ratio of 11b-HSD2 mRNA to 28S rRNA was calculated. For each experiment, the amount of 11b-HSD2 mRNA under various treatment conditions is expressed relative to the amount of transcript present in the untreated control.
Transient Transfection and Reporter Gene Assay
To determine if U0126 altered the rate of HSD11B2 gene transcription, a standard reporter gene assay was performed, as described [21] . Briefly, the isolated trophoblast cells were plated on 24-well plates and cultured under standard conditions for 48 h. The cells were then cotransfected with 0.8 lg/well of the pGL3-HSD11B2Pþ330bp and 0.2 lg/well of a cytomegalovirus promoter (pCMV) b-galactosidase plasmid (Promega Corporation), or with 0.8 lg/well pGL3-Basic and 0.2 lg/well pCMV-bGal (negative control). All transfections were carried out in serum-free medium 199 for 1 h using Transfast Transfection Reagent (Promega) at a ratio of 2:1 (transfection reagent to DNA) according to the manufacturer's instructions. At the end of transfection, cells were gently overlaid with fresh medium containing 10% serum and incubated for 4 h. The medium was then replaced with fresh medium containing 2% serum, and the cells were treated with 2 lM U0126 for 24 h. At the end of treatment, luciferase and galactosidase activities were analyzed using the Luciferase Assay System (Promega) and the b-Galactosidase Enzyme Assay System (Promega), respectively. Luciferase activity was measured using a Lumat LB 9507 luminometer (EG&G Berthold) and normalized against bgalactosidase activity. Each transfection was performed in triplicate, and a total of four independent experiments were carried out.
siRNA-Mediated Knockdown of ERK1/2 Expression
To provide additional evidence for the involvement of ERK1/2 signaling in regulating placental 11b-HSD2, a siRNA-mediated knockdown approach was utilized [14, 19] . Briefly, the isolated human trophoblast cells were plated on 24-well plates and cultured under standard conditions for 48 h. Cells were then transfected with 100 nM of Silencer Select siRNA targeting human ERK1 (Cat# S11141; Ambion) and ERK2 (Cat# S11137; Ambion) in Opti-MEM I medium (Invitrogen) containing 2 ll/well of Lipofectamine 2000 (Invitrogen), following the manufacturer's instructions. Cells were also transfected in an identical manner with 100 nM of the negative control #1 siRNA (Cat# 4624; Ambion) or with the transfection agent alone to serve as controls. At 60 h posttransfection, cells were collected for Western blot analysis, as described above.
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Statistical Analyses
Results are presented as mean 6 SEM of four to six independent experiments (i.e., tissues from different patients), as indicated. Data were analyzed using one-way ANOVA followed by Tukey post hoc test or Student ttest as indicated. Significance was set at P , 0.05. Calculations were performed using SPSS software version 9.0.
RESULTS
Effects of U0126 and SP600125 on ERK1/2 and JNK Phosphorylation
We previously demonstrated that p38 MAPK was a positive regulator of placental 11b-HSD2, but it remained unknown if the other two MAPKs, namely ERK1/2 and JNK, might also modulate placental 11b-HSD2. As a first step in examining this possibility, we determined the efficacy of U0126 and SP600125 (the two widely used pharmacological inhibitors) at inhibiting ERK1/2 and JNK activity, respectively, in cultured trophoblast cells. As shown in Figure 1 , treatment of trophoblast cells with 2 lM of U0126 and SP600125 led to a significant decrease in levels of phosphor-ERK1/2 proteins and phosphor-JNK protein, respectively. In contrast, the two pharmacological inhibitors had no effect on levels of total ERK1/2 proteins and JNK protein.
Effects of U0126 and SP600125 on 11b-HSD2 Activity and Expression
Having established their effectiveness to inhibit the activity of ERK1/2 and JNK, we then determined the effects of U0126 and SP600125 on 11b-HSD2 activity and expression. We first examined their effects on 11b-HSD2 activity, because changes in enzyme activity are more biologically meaningful than alterations in enzyme expression. We showed that treatment of trophoblast cells with U0126 led to a 3-fold increase in levels of 11b-HSD2 activity ( Fig. 2A) . By contrast, SP600125 had no effect (Fig. 2B) . Similar to its effect on 11b-HSD2 activity, U0126 treatment also resulted in a similar magnitude of increase in levels of both 11b-HSD2 protein (Fig. 2C) and mRNA (Fig. 2E) . Again, SP600125 did not alter either 11b-HSD2 protein (Fig. 2D) or 11b-HSD2 mRNA (Fig. 2F) .
Effects of U0126 and SP600125 on HSD11B2 Promoter Activity
The expression of placental 11b-HSD2 is regulated at both transcriptional and posttranscriptional levels. To determine whether ERK1/2 modulates HSD11B2 transcription, the effect of U0126 on HSD11B2 promoter activity was examined. Human trophoblast cells were transiently transfected with a luciferase construct containing the human HSD11B2 proximal promoter. As shown in Figure 3 , treatment with U0126 resulted in a 3-fold increase in HSD11B2 promoter activity, whereas treatment with SP600125 was ineffective.
Effects of siRNA-Mediated Knockdown of ERK1/2 Expression on 11b-HSD2
The increased 11b-HSD2 activity and expression following the inhibition of ERK1/2 activity with U0126 suggests that the ERK1/2 signaling pathway is a negative regulator of placental 11b-HSD2. To provide additional evidence, we used a loss of gene function approach. As shown in Figure 4A , transfection of trophoblast cells with siRNAs specific for human ERK1 and ERK2 resulted in a 78% reduction in levels of ERK1/2 proteins. Importantly, this led to a significant increase in the level of 11b-HSD2 protein (Fig. 4B) .
Effects of Cadmium on the Activity of MAPKs and PI3K
We previously demonstrated that cadmium decreased placental 11b-HSD2 expression via a transcriptional mechanism [15] , but the signal transduction pathway involved remains unclear. It is known that cadmium can signal through p38 MAPK, ERK1/2, JNK, and PI3K/Akt signaling pathways. Given that both inhibition of ERK1/2 activity with a pharmacological inhibitor and siRNA-mediated knockdown REGULATION OF PLACENTAL 11beta-HSD2 BY ERK1/2 of ERK1/2 expression led to increased 11b-HSD2 activity and expression in human trophoblast cells, we hypothesized that cadmium reduces placental 11b-HSD2 expression via activation of the ERK1/2 signaling pathway. As a first step in testing this hypothesis, we determined the effects of cadmium on the activity of the three MAPKs and PI3K/Akt. We found that treatment of trophoblast cells with cadmium led to rapid activation of ERK1/2, as reflected in increased levels of phosphor-ERK1/2 proteins. In contrast, cadmium did not alter the phosphorylation status of JNK, p38 MAPK, or PI3K/Akt (Fig. 5) .
Effects of U0126 on Cadmium Inhibition of 11b-HSD2
Having established the activation of ERK1/2 signaling pathway by cadmium, we then sought to determine if the ERK1/2 inhibitor U0126 could block cadmium-induced inhibition of placental 11b-HSD2. To do so, we pretreated trophoblast cells with U0126, and then treated them with and without cadmium. We showed that treatment with U0126 completely abrogated the inhibitory effects of cadmium on 11b-HSD2 activity (Fig. 6A) , 11b-HSD2 protein (Fig. 6B) , and 11b-HSD2 mRNA (Fig. 6C) .
DISCUSSION
In the present study we demonstrate that the ERK1/2 signaling pathway is a negative regulator of 11b-HSD2 activity and expression in cultured human trophoblast cells. We also provide evidence that the inhibitory effects of ERK1/2 on placental 11b-HSD2 are mediated at the level of HSD11B2 transcription. In addition, we provide evidence that cadmium represses placental HSD11B2 gene expression via activation of the ERK1/2 signaling pathway. Thus, the present findings indicate that the ERK1/2 signaling pathway is an important negative regulator of placental 11b-HSD2, and represents a key common pathway through which various intrinsic and environmental factors may exert their effects on placental 11b-HSD2, and consequently fetal development.
MAPKs regulate a diverse range of cell activities, including proliferation [22] [23] [24] , differentiation [25] , apoptosis [26] , and endocrine functions [27] of trophoblast cells. Recently, we have demonstrated that p38 MAPK enhances placental 11b-HSD2 expression by a posttranscriptional mechanism [14] . However, it remains unknown if the other two MAPKs, namely ERK1/2 and JNK, modulate placental 11b-HSD2. The present study was undertaken to address this question using primary human trophoblast cells as an in vitro model system. We showed that inhibition of ERK1/2 with the pharmacological inhibitor U0126 led to a 3-fold increase in levels of 11b-HSD2 activity, protein, and mRNA. By contrast, treatment of trophoblast cells with SP600125, a potent inhibitor of JNK, had no effect. Importantly, siRNA-mediated knockdown of ERK1/2 expression led to a similar increase in levels of 11b-HSD2 protein, as seen in cells treated with the ERK1/2 pharmacological inhibitor. Taken together, these observations suggest that ERK1/2 is a potent negative regulator of placental 11b-HSD2.
In theory, an increase in mRNA abundance can be achieved by either enhancing the rate of gene transcription and/or increasing mRNA stability (i.e., half-life). As a first step in determining the involvement of these two mechanisms, we studied the effects of U0126 on HSD11B2 promoter activity. We showed that treatment of trophoblast cells with U0126 resulted in a 3-fold increase in HSD11B2 promoter activity. Given that the magnitude of the increase in 11b-HSD2 mRNA and HSD11B2 promoter activity following treatment with U0126 was identical, we concluded that ERK1/2 downregulates 11b-HSD2 expression in human trophoblast cells by repressing HSD11B2 gene transcription. This is in marked contrast with our previous findings that p38 MAPK upregulates placental 11b-HSD2 by increasing the half-life of 
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11b-HSD2 mRNA [16] . Together, our present findings and those published previously provide persuasive evidence that the human placental 11b-HSD2 is under tight regulation by the two opposing actions of the p38 MAPK and ERK1/2 signaling pathways. Thus, it will be important not only to identify the upstream factors that activate these two signaling pathways but also to link them to alterations in placental 11b-HSD2 expression.
We demonstrated previously that cadmium inhibits placental 11b-HSD2 activity and expression by suppressing HSD11B2 gene transcription [15] . However, the signaling transduction pathway that mediates the effect of cadmium remains elusive. Given that ERK1/2 and cadmium exert similar inhibitory effects on placental 11b-HSD2, we hypothesized that cadmium down-regulates placental 11b-HSD2 through activation of the ERK1/2 signaling pathway. As a first step in examining this hypothesis, we determined the effect of cadmium on ERK1/2 activity as well as activities of other kinases that are known to be activated by cadmium in mammalian cells. Under conditions of the present study, we found that treatment of trophoblast cells with cadmium led to increased activity of ERK1/2. In contrast, cadmium did not alter activities of p38 MAPK, JNK, or PI3 kinase. This indicated that cadmium specifically activated the ERK1/2 signaling pathway in human trophoblast cells. However, given that a previous study showed that treatment of HTR-8/SVneo FIG. 5. Activation of ERK1/2 by cadmium. Human trophoblast cells were starved for 4 h in serum-free medium. Cells were then treated with 1 lM CdCl 2 in serum-free medium, and at indicated times thereafter cell lysates were prepared and subjected to standard Western blot analysis with antibodies specific for phosphorylated and total ERK1/2 proteins (A), phosphorylated and total JNK proteins (B; both antibodies detect JNK1 and JNK2), phosphorylated and total p38 proteins (C), and phosphorylated and total Akt proteins (D). Data are presented as mean 6 SEM of four independent experiments (*P , 0.05, ***P , 0.001 vs. 0 time point).
FIG. 6. Effects of U0126 on cadmium inhibition of 11b-HSD2 activity and expression. Human trophoblast cells were pretreated with 2 lM U0126 for 2 h and were then treated with 1 lM CdCl 2 for 24 h. At the end of treatment, levels of 11b-HSD2 activity (A), 11b-HSD2 protein (B) and 11b-HSD2 mRNA (C) were determined by a standard radiometric conversion assay, Western blotting, and qRT-PCR, respectively. Data are presented as mean 6 SEM of four independent experiments (***P , 0.001 vs. control).
REGULATION OF PLACENTAL 11beta-HSD2 BY ERK1/2 cells with 30 lM Cd led to increases in p-JNK and p-p38 MAPK [28] , it remains possible that cadmium may activate other signaling pathways besides ERK1/2 in human trophoblast cells with higher concentrations of and/or prolonged exposure to cadmium. To provide direct evidence for the involvement of ERK1/2 in mediating the inhibitory effects of cadmium on placental 11b-HSD2, we pretreated trophoblast cells with the ERK1/2 inhibitor U0126 followed by cadmium. We reasoned that if the inhibitory effects of cadmium on placental 11b-HSD2 are mediated by ERK1/2, the combined treatment of U0126 and cadmium should counteract each other's effects such that the net outcome should be similar to the control. Indeed, this was the case (i.e., U0126 completely abrogated cadmium-induced decreases in the level of 11b-HSD2 protein). Taken together, these findings suggested that cadmium represses placental 11b-HSD2 via activation of the ERK1/2 signaling pathway.
Our demonstration of ERK1/2 suppression of placental HSD11B2 gene expression adds a new dimension to our overall understanding of not only the regulation of placental 11b-HSD2 but also the role of this dynamic MAPK in normal and pathological pregnancies. We believe that the precise level of 11b-HSD2 in the human placenta is tightly controlled by a fine balance between stimulatory and inhibitory factors. The known stimulatory factors include estrogen [29] [30] [31] , human chorionic gonadotropin [32] , retinoic acids [33] and GCs [21, 34] , the actions of which are likely mediated by either the protein kinase A signaling pathway and/or the p38 MAPK signaling pathway, because both of these two signaling pathways have been shown to up-regulate placental 11b-HSD2 [14, 35, 36] . The known inhibitory factors consist of prostaglandins [37] , progesterone [38] , hypoxia [18, 39] , caffeine [16] , cadmium [15] , and peroxisome proliferator-activated receptor-d activation [40] . The actions of these inhibitory factors are likely mediated through the ERK1/2 signaling pathway, as demonstrated in the present study, and possibly through other signaling pathways that remain to be identified. Thus, it is possible that the ERK1/2 signaling pathway may contribute significantly to the molecular mechanisms underlying reduced placental 11b-HSD2 expression in pregnancies complicated with FGR.
In summary, our present data demonstrate that ERK1/2 is a potent negative regulator of 11b-HSD2 in the human placenta, and cadmium represses placental 11b-HSD2 expression via activation of the ERK1/2 signaling pathway. If these in vitro findings could be extrapolated to the human placenta in vivo, they would suggest that the ERK1/2 signaling pathway might represent an attractive therapeutic target for preventing and/or reversing FGR resulting from exposure to cadmium via smoking and other dietary sources. In addition, given that ERK1/2 is abundantly expressed in the human placenta where its function is largely unknown, our present study also reveals 11b-HSD2 as an important target through which ERK1/2 may regulate human placental function and consequently fetal growth and development.
